Valion Bio, Inc. — Form SCHEDULE 13D/A
Filed August 24, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 72/100
What the filing says
3i, LP converted 2,020,404 shares of Series C Preferred Stock at $0.39/share (≈$788k) on 08-20-2026, then sold 443,361 common shares over three days (08-20 to 08-24-2026) at prices ranging $0.1143–$0.1763, realizing ≈$64k gross. This represents a shareholder converting a large preferred position and immediately liquidating common stock at significantly lower prices than conversion cost.
Why this rating
Conversion + immediate sales equal ~$852k in shareholder activity—21% of $4M market cap. Signals lack of confidence; preferred holder liquidating at 70% discount to conversion price is material to tiny company.
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.